We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+1.26%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$4.8B
AUM Growth
-$159M
Cap. Flow
-$187M
Cap. Flow %
-3.89%
Top 10 Hldgs %
18.32%
Holding
695
New
64
Increased
242
Reduced
263
Closed
62

Top Sells

Rank Stock Value
1
EWJ icon
iShares MSCI Japan ETF
EWJ
+$40.8M
2
INTU icon
Intuit
INTU
+$32.8M
3
META icon
Meta Platforms (Facebook)
META
+$30.3M
4
MA icon
Mastercard
MA
+$28.3M
5
NKE icon
Nike
NKE
+$25.9M

Sector Composition

Rank Sector Weight
1 Healthcare 29.43%
2 Financials 13.37%
3 Technology 9.86%
4 Consumer Discretionary 7.77%
5 Industrials 7.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MO icon
226
Altria Group
MO
$122B
$5.33M 0.11%
109,020
-64,437
-37% -$3.27M
CLVS
227
DELISTED
Clovis Oncology, Inc.
CLVS
$5.27M 0.11%
60,000
-10,000
-14% -$856K
SAGE
228
DELISTED
Sage Therapeutics
SAGE
$5.26M 0.11%
72,000
-7,000
-9% -$450K
AKRX
229
DELISTED
Akorn Inc
AKRX
$5.15M 0.11%
118,000
+93,000
+372% +$4.3M
GDX icon
230
VanEck Gold Miners ETF
GDX
$23B
$5.15M 0.11%
+290,000
New +$5.64M
FTI icon
231
TechnipFMC
FTI
$30.6B
$5.12M 0.11%
165,726
+40,106
+32% +$1.23M
GHDX
232
DELISTED
Genomic Health, Inc.
GHDX
$5.11M 0.11%
184,000
+73,000
+66% +$2.06M
MGNX icon
233
MacroGenics
MGNX
$235M
$5.09M 0.11%
134,000
-91,000
-40% -$2.99M
NBIX icon
234
Neurocrine Biosciences
NBIX
$17.7B
$5.01M 0.1%
105,000
-50,000
-32% -$2.12M
TGTX icon
235
TG Therapeutics
TGTX
$8.58B
$4.98M 0.1%
300,000
-30,000
-9% -$475K
MFC icon
236
Manulife Financial
MFC
$72.6B
$4.97M 0.1%
267,169
-473,220
-64% -$8.79M
OMG
237
DELISTED
OM GROUP INC.
OMG
$4.96M 0.1%
+147,725
New +$4.59M
KYTH
238
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$4.86M 0.1%
+64,476
New +$3.45M
KSS icon
239
Kohl's
KSS
$2.03B
$4.81M 0.1%
76,753
-221,699
-74% -$15.4M
PAYX icon
240
Paychex
PAYX
$40.4B
$4.76M 0.1%
101,488
-186,523
-65% -$9.12M
BNY
241
Bank of New York Mellon
BNY
$108B
$4.74M 0.1%
113,044
+95,790
+555% +$4.08M
HCC
242
DELISTED
HCC INSURANCES HOLDINGS INC
HCC
$4.71M 0.1%
+61,264
New +$3.81M
DVN icon
243
Devon Energy
DVN
$51.9B
$4.66M 0.1%
78,326
-1,956
-2% -$126K
IONS icon
244
Ionis Pharmaceuticals
IONS
$9.35B
$4.6M 0.1%
80,000
-20,000
-20% -$1.27M
GS icon
245
Goldman Sachs
GS
$313B
$4.56M 0.09%
21,843
-1,112
-5% -$227K
TSRO
246
DELISTED
TESARO, Inc.
TSRO
$4.53M 0.09%
77,000
-63,000
-45% -$3.61M
MCK icon
247
McKesson
MCK
$98.5B
$4.48M 0.09%
19,918
-2,215
-10% -$512K
ISEE
248
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.42M 0.09%
85,000
-51,000
-38% -$2.54M
AGEN
249
Agenus
AGEN
$249M
$4.4M 0.09%
25,985
-5,604
-18% -$795K
KITE
250
DELISTED
Kite Pharma, Inc.
KITE
$4.39M 0.09%
72,000
-8,000
-10% -$456K

Similar funds

Candriam SCA's Q2 2015 Portfolio in Review

As of Q2 2015, Candriam SCA held 695 positions worth $4.8B, down 3.2% from $4.96B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Candriam SCA withdrew a net $187M in Q2 2015, closing 62 positions and reducing 263 holdings. Its most notable exit was iShares MSCI Japan ETF, an estimated $40.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, up from 28% a quarter earlier, followed by Financials and Technology.

Against the trend, Candriam SCA opened a new position in American Airlines Group worth $11.6M.

  • Candriam SCA's largest Q2 2015 buy was American Airlines Group: 290,014 shares worth $11.6M.
  • Candriam SCA added most to Alphabet (Google) Class C in Q2 2015, an estimated $33.8M increase.
  • Candriam SCA's biggest Q2 2015 reduction was Intuit, cutting an estimated $32.8M.
  • Candriam SCA fully exited iShares MSCI Japan ETF in Q2 2015, selling an estimated $40.8M.
  • Candriam SCA's ten largest holdings make up 18% of its $4.8B portfolio in Q2 2015.
  • Candriam SCA opened 64 new positions and closed 62 in Q2 2015.
  • Candriam SCA's portfolio value fell 3.2% quarter-over-quarter to $4.8B.

Based on Candriam SCA's 13F filing for Q2 2015, filed 29 Jul 2015.